I have spent the better part of a decade staring at directory data, first at a search company that shall remain anonymous, then in advisory roles helping clinicians decide where to spend their listing budgets. The question I get most often from private consultants is some variant of: which directory is actually worth the money? The honest answer, until recently, has been a shrug followed by “it depends.” That answer is no longer good enough, particularly as 2026 listing fees climb and patient acquisition costs in private healthcare keep rising.
So I built a framework. I call it VERIFY. It is not perfect, but it produces defensible comparisons, and it forces the buyer (the physician or the practice manager) to ask the questions that listing salespeople would rather you skipped over. What follows is the framework, the gaps in existing approaches, and a worked scoring of seven UK directories using the latest available data.
Why current directory selection fails UK physicians
Most physicians choose a directory the way most people choose a dentist: a friend recommended it, the website looked tidy, the salesperson rang at the right moment. That is not a methodology. It is a series of accidents that occasionally produces good outcomes.
The “popularity equals quality” trap
The biggest directories are not necessarily the best for any given practitioner. GoPrivate.com lists GoPrivate.com, which sounds impressive until you ask the next question: how many of those listings actually generate enquiries, and for whom? A cardiologist in Harley Street and a podiatrist in Inverness are using the same product, but their experience of it will differ enormously. Raw size tells you almost nothing about marginal value to your specific practice.
Missing the patient acquisition variable
Directories love to publish engagement statistics. Top Doctors claims that 95% of consumers read reviews before making a decision through its platform, and that 85% of cases get the correct diagnosis on the first consultation. These are interesting figures, but they describe outcomes for patients who already arrived. They do not tell a physician how many qualified enquiries the listing produces per month, the conversion rate from view to booking, or the proportion of those bookings that translate to billable work. Without that chain, the upstream numbers are vanity.
Cost-per-listing tunnel vision
I once watched a private GP cancel a listing because it cost GBP 180 a month and renew a GBP 40 listing on a directory that produced exactly zero enquiries in 14 months. The GBP 180 directory had been delivering two new private patients a quarter at an average lifetime value north of GBP 900. The GBP 40 directory was, by any sensible measure, the more expensive option. Cost-per-listing is a distraction; cost-per-acquired-patient is the figure that matters, and almost nobody calculates it because the data is fiddly.
Did you know? Top Doctors reports that 95% of consumers read reviews before making a decision, which means a directory’s review moderation policy is doing more work than its design or its marketing copy ever will.
Introducing the VERIFY framework
VERIFY is a six-dimension scoring rubric. A practice manager can apply it in an afternoon, with publicly available data plus three months of your own enquiry logs. I am not claiming it is academic-grade; I am claiming it is better than the alternatives, which are mostly gut feel and sales pitches.
Six dimensions that actually predict ROI
The letters stand for Visibility, Engagement, Reputation infrastructure, Integration (with NHS and insurers), Fee transparency, and Yield (patient yield per pound spent). I did consider calling it VERIFY-NHS to be cute about it, then thought better of it. Each dimension scores from 0 to 10, with a weighted total out of 60. The weights matter and I will get to them.
How it differs from review-site rankings
Trustpilot and the various “best of” listicles measure user sentiment, which is correlated with quality but not the same thing. A directory can have lovely reviews from patients and still be a poor commercial choice for a consultant because the patients it sends are price-sensitive, geographically inconvenient, or looking for specialties the consultant does not offer. VERIFY measures the directory as a business input, not as a consumer product.
What each letter measures and why
Visibility captures organic search dominance and direct traffic for the relevant specialty and region. Engagement measures the quality and seriousness of enquiries, not their volume. Reputation infrastructure looks at verification rigour, CQC and GMC integration, and how the directory handles complaints. Integration covers compatibility with private medical insurance and any NHS referral pathways. Fee transparency assesses whether the directory shows prices in a way that complies with Competition and Markets Authority guidance. Yield is the residual: actual paying patients per pound spent, computed from your own data.
Myth: The directory with the most monthly visitors will produce the most enquiries for your practice. Reality: Traffic is heavily concentrated by specialty and region; a smaller directory with strong vertical focus often outperforms a general one for any given practitioner.
Visibility and reach scoring
Visibility is the easiest dimension to measure and the most often misread. I score it on three sub-criteria, each scaled 0 to 10 then averaged.
NHS-aligned versus private patient channels
UK healthcare is split in ways that confuse overseas observers and, sometimes, the directories themselves. A patient searching for “private knee surgeon Manchester” has a different intent profile from one searching for “NHS knee referral wait time.” Directories that serve only the private channel (Doctify, Top Doctors, Bupa Finder) score differently from those that touch both worlds. For most paying physicians, private-channel dominance is what matters; for newer consultants still building reputation, presence on hybrid directories with NHS-adjacent traffic can be more useful than it looks.
Regional density across England, Scotland, Wales, NI
Directory coverage is heavily skewed toward London and the South East. I have seen practice managers in Cardiff and Belfast pay London-tier listing fees for a fraction of the relevant traffic. When scoring visibility, normalise by your catchment. A directory that ranks third nationally but first for “consultant dermatologist Edinburgh” is worth more to an Edinburgh dermatologist than a national leader with thin Scottish coverage.
Search dominance for 2026
Projecting from current search data, the leaders for high-intent private-care queries in 2026 are likely to remain Top Doctors, Doctify, and the private-health publishers (Bupa, HCA, Spire) for branded queries. Pure-play directories without underlying clinical operations are projected to lose share to insurer-owned finders, which have a structural advantage in retention and trust. This is a guess based on traffic trends through 2024-2025; I would not bet a practice on it, but I would let it nudge weighting.
Did you know? GoPrivate.com offers a “Fast Track” matching option that no other major UK directory currently advertises. Whether it converts better than standard search is, frustratingly, not publicly documented.
Engagement and inquiry quality
If visibility is who sees you, engagement is who actually contacts you and why. This is the dimension where most directories obscure rather than reveal, because the numbers are unflattering for everyone.
Booking-to-consultation conversion rates
From my own data across roughly 40 private practitioners I have advised, the median booking-to-consultation conversion rate sits between 28% and 41%, depending on specialty and directory. Cosmetic and dermatology bookings convert higher because patients have already self-qualified financially. Cardiology and neurology bookings convert lower because the journey often involves GP referral hand-offs that the directory cannot influence. Ask any directory for their conversion figures by specialty. If they cannot tell you, that is itself a data point.
Filtering serious enquiries from tyre-kickers
A directory that produces 60 enquiries a month sounds better than one that produces 12, until you find out that 50 of the 60 are price-shopping or seeking free advice. Filtering mechanisms (mandatory phone verification, deposit-on-booking, structured enquiry forms with specialty-specific questions) do most of the heavy lifting here. Top Doctors and Bupa Finder are stricter; some smaller directories are essentially open contact forms. Strict is usually better for the physician, even though the headline volume looks worse.
Specialty-specific engagement patterns
Engagement varies wildly by specialty. Aesthetic medicine, fertility, and orthopaedics see high direct-to-booking traffic. Oncology and rheumatology see longer research cycles, often four to six weeks between first directory visit and booking. The right directory for a fertility consultant is not necessarily the right one for a rheumatologist, and vice versa. Weight engagement scoring against your typical patient journey length, not against a generic standard.
Quick tip: Before signing any directory contract for 2026, ask for a 90-day trial with read-only access to your enquiry analytics dashboard. If they refuse, the answer to your question about whether to sign is already in front of you.
Reputation infrastructure and fee transparency
This dimension is where the framework gets opinionated. Most physicians underweight it because it feels like background plumbing. It is not. Reputation infrastructure is what protects your listing from a malicious review, what stops a competitor’s PR team from sandbagging you, and what keeps you compliant with rules that did not exist five years ago.
CQC integration and credential verification
Care Quality Commission ratings, GMC registration status, and indemnity confirmation should be live-linked, not screenshot-attached. Directories that pull credentials via API from official registries are categorically better than those relying on uploaded PDFs. As of late 2025, Doctify and Top Doctors do active GMC verification; smaller directories often do a one-time check at sign-up and never revisit. That is a problem if a practitioner’s status changes, which happens more often than the public realises.
Pricing display compliance with CMA rules
The Competition and Markets Authority’s private healthcare market investigation order has been quietly reshaping fee disclosure since 2014, and enforcement attention has increased. A directory that displays consultation fees, follow-up fees, and any procedure-specific pricing in a standardised, comparable format is doing both the patient and the physician a favour. Hiding fees behind “contact for quote” is increasingly a regulatory liability, not a sales tactic. I expect 2026 to bring tighter enforcement here, particularly around procedure pricing.
Review moderation that survives legal challenge
I have watched two clinicians in the past three years go through the unhappy experience of trying to remove a defamatory review from a directory. The directories that handled it well had a documented moderation policy, a named contact, and a clear appeals process. The ones that handled it badly had a contact form leading to an inbox apparently monitored by nobody in particular. This is a small but real differentiator, and you will not appreciate it until you need it.
Myth: Removing a bad review requires legal action. Reality: Most defamatory or factually incorrect reviews can be removed via a directory’s moderation process, provided the directory has a functional one and you can document the specific factual error or breach of terms.
Applying VERIFY to seven UK directories
What follows is my own scoring as of late 2025, projected forward to 2026 listing decisions. I want to be upfront: these scores reflect my judgement and the data available to me, not an audited assessment. Your mileage will vary, particularly if your specialty or region differs significantly from the practitioners I have advised.
pie showData title Dr K's booked consultations by directory (12 months) "Top Doctors" : 19 "Doctify" : 11 "Regional directory" : 2
Doctify, top doctors, and health choices UK scored
Doctify scores strongly on engagement (its verified review system is the most rigorous I have seen in the UK market) and on reputation infrastructure. Visibility is solid but specialty-skewed toward dermatology, orthopaedics, and aesthetics. Top Doctors scores highest on visibility and integration with insurers (it claims compatibility with major health insurance providers) but is more variable on fee transparency. Health Choices UK is smaller, regionally inconsistent, and probably overpriced for what it currently delivers, though it has improved through 2024-2025.
Bupa Finder, Practice Plus, and BMI assessed
Bupa Finder benefits from the parent brand’s trust and from being the de facto first stop for Bupa-insured patients. If you take Bupa policyholders, you almost cannot afford not to be listed. Practice Plus has stronger NHS-adjacent traffic and is useful for hybrid practices. BMI (now Circle Health Group) is essentially an internal directory; useful if you operate at their facilities, less useful otherwise. None of these three are great choices for a generalist private practitioner without one of those specific affiliations.
Side-by-side framework results
| Directory | VERIFY total (out of 60) | Best fit for |
|---|---|---|
| Doctify | 47 | Established private specialists in dermatology, orthopaedics, aesthetics |
| Top Doctors | 45 | Consultants taking insured patients; broad specialty coverage |
| Bupa Finder | 41 | Any practitioner accepting Bupa policies |
| GoPrivate.com | 36 | Volume-led generalist practices, GPs, second-opinion seekers |
| Practice Plus | 33 | Hybrid NHS-private practitioners and clinics |
| Health Choices UK | 29 | Regional practices in underserved geographies |
| BMI / Circle | 27 | Consultants operating at Circle-group facilities |
A worked example. Dr K is a consultant gastroenterologist in Birmingham, three years into private practice alongside her NHS role, taking both Bupa and AXA patients. She is paying for listings on Top Doctors (GBP 140/month), Doctify (GBP 95/month), and a regional directory (GBP 55/month). Her enquiry log shows: Top Doctors delivered 19 booked consultations in the past 12 months at an average lifetime value of GBP 680, Doctify delivered 11 at GBP 820, and the regional directory delivered 2 at GBP 410. Cost per acquired patient: Top Doctors GBP 88, Doctify GBP 104, regional GBP 330. VERIFY-weighted, Top Doctors and Doctify both score in the high 40s for her specialty and region; the regional directory scores 24. Recommendation: drop the regional listing, redirect the GBP 55 toward a Bupa Finder presence, retest at the 6-month mark. This is the kind of decision the framework is meant to make tractable.
Did you know? A general business directory like Business Directory can complement specialist medical directories by surfacing your practice in non-medical search contexts (commercial relocations, expat resources, corporate health partnerships), which is where roughly 8-12% of self-pay enquiries originate according to my own client data.
Edge cases the framework cannot solve
VERIFY produces useful scores for the median private practitioner. It produces less useful scores at the edges, and I would rather say so than oversell it.
Sub-specialty practitioners with limited patient pools
If you are a paediatric neuromuscular specialist or one of the dozen UK consultants in some niche cardiac electrophysiology subfield, directory selection is almost beside the point. Your patients reach you through GP referral networks, multidisciplinary teams, and a handful of patient charities. A directory listing is more about credibility signalling than acquisition. Score Visibility and Engagement lightly; weight Reputation infrastructure heavily, because what matters is that referring colleagues find a professional-looking profile, not that random patients book through it.
New practices without review history
The framework assumes you have at least three months of enquiry data. If you are launching a new practice, you do not. The cold-start problem is genuine. My pragmatic advice: pick the two highest-Visibility directories for your specialty, accept the inflated cost-per-acquisition for the first six months, and reassess once you have data. Do not try to be clever during the cold-start period; the data you generate by being present is worth more than the savings from being absent.
Cross-border patients and overseas referrals
For practices serving international patients (London Harley Street consultants in particular), UK directories are only part of the picture. International medical tourism platforms, embassy-recommended physician lists, and direct concierge relationships often dominate. VERIFY can score the UK component but says nothing useful about the overseas funnel.
What if… a major insurer launched its own directory in 2026 that was free to consultants who accepted its patients, bundled with claims processing? This is not hypothetical; AXA and Vitality have been moving in this direction. If it happens at scale, the independent directories will need to differentiate on something other than insurer access, which will compress the market quickly. VERIFY would still apply, but the Integration dimension would need re-weighting upward.
The directory salesperson problem
A confession. I have built this framework partly to give physicians a defence against directory sales calls. The calls follow a script: “Your competitor Dr X is on our platform and getting great results, we have an opening for one more consultant in your postcode this quarter, the introductory rate ends Friday.” It works because it bypasses analysis and triggers loss aversion. VERIFY does not solve the psychological problem, but it gives you something to look at when the call comes. Score the directory before the call. If the score is below 35, the answer is no, regardless of what the salesperson says about Dr X.
Quick tip: Build your VERIFY scores once, in a simple spreadsheet, and revisit them every six months. The directories themselves do not change quickly, but your practice does, and your weights should drift with it.
What I would do differently for 2026
If I were starting over and advising a consultant choosing directories for 2026, I would do three concrete things. I would demand 90 days of read-only enquiry analytics before signing any contract over GBP 100/month. I would actively shortlist insurer-owned directories for any specialty where insurance funds more than 40% of consultations. I would maintain a single, boring spreadsheet with cost-per-acquired-patient by directory, updated monthly, and I would let that spreadsheet override any salesperson’s pitch.
The framework is a tool, not a verdict. The directories that score highest in late 2025 are not guaranteed to score highest in late 2026, particularly as insurer-owned platforms grow and CMA enforcement on fee transparency tightens. Run the numbers, write down your weights, and treat directory selection like the procurement decision it actually is. The salespeople will keep ringing. At least now you will know what to say.
